Cerulean CEO Fetzer takes reins at Venter's Synthetic Genomics; ImevaX raises $9.5M for vaccine work;

@FierceBiotech: $AMGN, $SNY and Ono band together for open-source R&D. Article | Follow @FierceBiotech

@JohnCFierce: Amgen adds up to 1,100 new job cuts to its global restructuring plan - Wall Street loves it, shares up 5%. News | Follow @JohnCFierce

@DamianFierce: $RNA CEO on $SRPT's setback: "We are all in this together." More from CNBC | Follow @DamianFierce

@EmilyMFierce: Salk's 100th: Anti-Vaccination Would Trouble Polio Hero. More from LiveScience | Follow @EmilyMFierce

> Cerulean CEO Oliver Fetzer has jumped ship, taking the top job at Craig Venter's Synthetic Genomics in La Jolla. Cerulean board member Paul Fetzer has been named executive chairman in a reshuffle. Release

> Germany's ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, has wrapped a $9.5 million Series A financing round. Release

Medical Device News

@FierceMedDev: IPOs: Sientra goes for $75M, while Nevro nerves up for $100M. Report | Follow @FierceMedDev

@VarunSaxena2: Here's my pernicious article. Read it are your own risk. ICYMI yesterday | Follow @VarunSaxena2

@EmilyWFierce: Find out which companies struck gold in the pharma M&A frenzy in FiercePharma's latest special report. Report | Follow @EmilyWFierce

> HealthTrust commits to buying Infraredx coronary imaging tech. Item

> Welch Allyn partners with startup Gentag to create wearable devices. More

> Wright, Tornier merge in $3.3B inversion deal to create extremities and biologics pure play. News

Pharma News

@FiercePharma: Tops in FierceAnimalHealth: Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Story | Follow @FiercePharma

@EricPFierce: Ranbaxy's New Jersey plant comes through for drugmaker. More  | Follow @EricPFierce

@CarlyHFierce: Our newest special report is live! Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Big relief for Lilly, Boehringer as judge slashes $9B Actos award by 99%. Report

> Pfizer beats the Street's Q3 expectations but stays mum on AZ deal. Article

> Novartis gets 4% sales lift as 'growth products' make good on their label. Story

> Looming trouble in Sanofi's diabetes biz turns up the heat on CEO. More

Biotech Research News

> Government halts research on dangerous airborne pathogens. Item

> Toxin-producing stem cells designed to kill brain cell tumors. Report

> Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. Story

> Case Western, Janssen, Oncodesign scientists ID anti-inflammatory compounds. More

> Protein discovery could help kill stubborn latent HIV. Article

Pharma Manufacturing News

> Australia's CSL gets three Novartis vaccine plants in $275M deal. News

> Ranbaxy's New Jersey plant comes through for drugmaker. Item

> Hikma gets FDA warning letter for plant in Portugal. More

> Fujifilm adding Texas-based vaccine specialist to its fold. Story

> U.S. Attorney subpoenas Novo for info on Denmark plant. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.